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events in a case of recurrent
nasopharyngeal carcinoma undergoing
anti-PD-1 immunotherapy
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Abstract
Background: Treatment of recurrent nasopharyngeal carcinoma is a challenging clinical problem. We report the
case of a 46 year old male showing excellent response and signs of immunostimulation following re-re-irradiation
for recurrent nasopharyngeal carcinoma under systemic treatment with pembrolizumab.
Case presentation: Patient was first diagnosed with locoregionally advanced, non-keratinizing nasopharyngeal
carcinoma in 2010. After achieving complete remission following induction chemotherapy and concurrent curative
chemoradiation, the patient subsequently developed distant and locoregionally recurrent disease. He received various
treatments (neck dissection, radiotherapy to a bony metastasis, palliative chemotherapy, stereotactic re-irradiation of local
recurrence) before initiation of anti- PD-1 immunotherapy with pembrolizumab in January of 2016. Following marked
local progression 6 months thereafter, we performed re-re-irradiation of the recurrent tumor after careful evaluation and
treatment planning. While treatment was well tolerated, the patient subsequently developed marked clinical and
radiological signs of immunostimulation with mucosal irritation and swelling of lacrimal and salivary glands as
described in the report. Immunotherapy with pembrolizumab was reinitiated, with re- staging showing excellent
response with regression of all tumorous lesions. At the time of this report, following near complete recovery of
inflammatory symptoms, the patient remains in excellent condition and free from recurrence under treatment
with pembrolizumab.
Conclusions: To our knowledge, we report the first observation of a combined effect of immunotherapy and
radiotherapy in a patient with recurrent nasopharyngeal carcinoma. Demonstrating distinct signs of immunostimulation
as well as excellent tumor response in a heavily pretreated patient progressing under anti-PD-1 immunotherapy, the
case adds to the rising paradigm of an immunostimulatory effect of radiotherapy in patients undergoing treatment with
immune checkpoint inhibitors.
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Background
Treatment of recurrent nasopharyngeal carcinoma is a
challenging clinical problem. We report the case of a
46 year old male showing excellent response and signs of
immunostimulation following re-re-irradiation for recur-
rent nasopharyngeal carcinoma under systemic treatment
with pembrolizumab.
Case presentation
Patient was originally diagnosed with locoregionally
advanced, non-keratinizing nasopharyngeal carcinoma
(stage IVB; cT2 cN3a cM0; EBV-associated) in November of
2010 (Fig. 1). He underwent treatment with neoadjuvant
chemotherapy (two 3-weekly cycles of cisplatin 100 mg/m2
d1 and fluorouracil 1000 mg/m2 d1–4) followed by
concurrent curative chemoradiation. Intensity-modulated
radiotherapy (volumetric modulated arc therapy; VMAT)
was delivered to the primary tumor and nodal metastases
in 35 daily fractions of 2 Gy to a total dose of 70 Gy as an
integrated boost with elective nodal irradiation to 54 Gy
(Fig. 2). Due to cisplatin-induced ototoxicity and anaphyl-
actic reaction to cetuximab, concurrent chemotherapy
was delivered with 4 cycles of carboplatin 100 mg/m2
weekly (stopped prematurely due to thrombocytopenia).
Having achieved complete remission, the patient first
presented with distant and locoregionally recurrent
disease in October 2011, with PET-CT showing a highly
suspicious FDG-avid lesion in the thoracic spine which
was diagnosed as bony metastasis after further examin-
ation in contrast-enhanced MRI (additional biopsy was
omitted after interdisciplinary discussion since clinical
significance was deemed low). The patient received
radiotherapy (45 Gy in fractions of 3 Gy) to the solitary bony
metastasis as well as bilateral neck dissection, removing a
total of three metastatic lymph nodes of the left neck.
He was subsequently free from recurrence and without
symptoms for two years, allowing him to work full-time.
In September of 2013, PET-CT and MRI first raised
suspicion of a small bony metastasis of the right occipital
condyle and the adjacent clivus. Since this region bordered
the initial primary tumor and had therefore received the
full dose of 70 Gy during chemoradiation, re-irradiation
was declined, given that the patient was asymptomatic.
However, the patient developed progressive diplopia due
to right-sided abducens nerve palsy after a few weeks. A
biopsy of the occipital condyle was performed, confirming
cancer recurrence. Due to surrounding dural thickening
and contrast enhancement suspicious of meningeal car-
cinomatosis, the patient received one cycle of intrathecal
methotrexate; however, lumbar puncture did not show
malignant cells. The patient subsequently received 4 cycles
of combination chemotherapy (carboplatin, fluorouracil,
docetaxel) with good radiological and clinical response.
Due to progressive diplopia in September of 2014, an
MRI was performed, showing tumorous infiltration of
the cavernous sinus affecting the abducens nerve. The
patient underwent stereotactic re-irradiation (single fraction
of 14 Gy to the cavernous sinus) at an external institution
using CyberKnife®, achieving mild improvement of symp-
toms. Due to allergic reaction to carboplatin, systemic treat-
ment was switched to docetaxel and gemcitabine for a total
of 6 cycles. The patient was again free from disease progres-
sion for one year, before developing tumor progression at
the skull base involving the cavernous sinus, Meckel’s cave
and the internal carotid artery on the right side as well
the middle cranial fossa including the hypoglossal canal
in autumn of 2015.
Following the presentation of promising preliminary
data for heavily pretreated patients with nasopharyngeal
carcinoma in the KEYNOTE-028 cohort [1], a request
for medical insurance coverage of immunotherapy with
pembrolizumab was made whilst re-challenge chemotherapy
with docetaxel and gemcitabine was administered during
the decision process. Having received approval, immuno-
therapy with pembrolizumab was initiated in January of
2016. At this point, PET-CT did not show any distant
metastases and circulating EBV DNA (a biomarker for
nasopharyngeal carcinoma) was not measurable.
Fig. 1 T1-weighted MRI in November of 2010 showing contrast-enhancing right-sided nasopharyngeal primary tumor (red arrow) as well as bilateral
metastatic lymph nodes of the neck (blue arrows)
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While restaging 3 months after initiation of pembrolizu-
mab demonstrated an overall stable situation, the patient
progressed again in June of 2016 after 6 months of
pembrolizumab, with MRI showing marked increase of
tumorous infiltration in the cavernous sinus, Meckel’s
cave, the right carotid artery, the occipital condyle as well
as the prevertebral space (Fig. 3). During the same period,
the patient developed clinical symptoms with progressive
trismus, right sided hypoglossal and glossopharyngeal
nerve palsy with dysphagia as well as right sided facial
hypesthesia, fitting the radiological diagnosis of pro-
gressive disease rather than pseudoprogression under
immunotherapy. Since the tumor remained unresectable
(large tumor extension affecting dura, cavernous sinus,
clivus and internal carotid artery without realistic chance
of achieving an R0 resection), the patient was once again
presented for radiotherapy. After careful evaluation and
treatment planning, we performed stereotactic image-
guided re-re-irradiation of the recurrent lesion to a total
dose of 45 Gy in 25 daily fractions of 1.8 Gy over 6 weeks
(Fig. 4). Immunotherapy with pembrolizumab was paused
during radiotherapy, which was completed in early
October of 2016. Apart from marked fatigue, irradiation
was well tolerated, with only mild dysphagia and two
episodes of nausea (self-limiting without need for steroids).
Two weeks after treatment completion, the patient
first reported symptoms of a common cold with nasal
congestion. The patient was seen by our otorhinolaryn-
gologists and received symptomatic treatment and anti-
biotics (amoxicillin / clavulanic acid) due to thick, putrid
mucus in the nasal cavity and the nasopharynx. The
patient also reported symptoms of ocular irritation with
a burning sensation, dryness and epiphora as well as
pronounced swelling of the eyelids in the early morning, also
receiving symptomatic treatment after consultation with our
ophthalmologists. Having achieved some symptomatic
improvement, the patient then presented with a painful
swelling of the left submandibular gland suspicious of
sialadenitis without sonographic signs of sialolithiasis
(fine-needle aspiration was refused by the patient). Days
later, he also developed an itching maculopapular rash on
the whole body with skin biopsy showing perivascular
lymphohistiocytic infiltration mixed with eosinophils. Sus-
pecting cutaneous drug eruption caused by amoxicillin,
Fig. 2 Intensity-modulated radiotherapy plan of 2010 showing 95%-isodose coverage of bilateral cervical lymph nodes with simultaneous
integrated boost (SIB) of 70 Gy to the primary tumor and metastatic lymph nodes
Fig. 3 T1-weighted MRI in June of 2016 showing bulky tumor recurrence (red arrows) in axial and coronal plane
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our dermatologists prescribed topical and systemic steroids
which led to slow recovery (over 6 weeks).
Treatment with pembrolizumab was ultimately reinitiated
7 weeks after completion of radiotherapy, and we performed
a re-staging with PET-CT and MRI in December of 2016,
showing an excellent response with regression of all
tumorous lesions (Fig. 5). Notably, a marked swelling of
the lacrimal and salivary glands was observed (Fig. 6),
which we interpreted as a sign of increased immunologic
response to immunotherapy following irradiation. Treat-
ment with pembrolizumab was continued and well toler-
ated, with slow regression of the inflammatory symptoms
described above as well as remarkable neurological
improvement (dysphagia, diplopia, trigeminal function).
Fittingly, re-staging MRI in February and May of 2017
showed an ongoing response with further regression of
the tumorous lesions in MRI (Fig. 7). Following near
complete recovery of inflammatory symptoms, PET-MRI
in August of 2017 showed regression of inflammatory
signs as well as ongoing local control without distant
metastases (almost 6 years after first receiving radio-
therapy for a bony metastasis). At the time of this
report, the patient is in excellent condition, continuing
treatment with pembrolizumab as well as rehabilitative
treatments under regular follow-up.
Discussion
Treatment of recurrent nasopharyngeal carcinoma remains
a significant clinical problem, with local recurrence
representing a major cause of mortality and morbidity
[2]. Management of these patients is challenging, with
salvage strategies including surgery as well as various
forms of radiotherapy (external intensity-modulated
radiotherapy (IMRT) including stereotactic radiotherapy
or radiosurgery, proton irradiation, brachytherapy) with or
without chemotherapy [2–16].
Fig. 4 Treatment plan for stereotactic re-re-irradiation using rotational intensity-modulated radiotherapy (volumetric modulated arc therapy; VMAT). The
95%-isodose coverage of the prescribed 45 Gy is shown on fused MRI in axial and sagittal plane, with the latter demonstrating extensive craniocaudal
(including prevertebral) tumor extension
Fig. 5 T1-weighted MRI in December of 2016 showing excellent subtotal tumor response following re-re-irradiation in sagittal, coronal and axial plane
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We assume that the case discussed demonstrates
distinct signs of a combined effect of immunotherapy
and radiotherapy in a heavily pretreated patient with
recurrent nasopharyngeal carcinoma progressing under
anti-PD-1 immunotherapy. To our knowledge, it is thus
the first reported observation of such an effect in a patient
with recurrent nasopharyngeal carcinoma. Showing both
an excellent local response as well as clinical and radio-
logical inflammatory signs outside of the radiation field, the
case adds to the rising paradigm of an immunostimulatory
effect of radiotherapy in patients undergoing therapy with
immune checkpoint inhibitors [17–19].
While differentiating delayed effects of immunotherapy
from responses caused partially or completely by local
treatment is intrinsically difficult, the chronological associ-
ation with radiotherapy as well as the regional distribution
of inflammatory effects (not solely accountable to direct
radiation effects due to the dose distribution) seem
striking. Since the first clinical signs of a possible
immunostimulation appeared 10 months after initiation
of pembrolizumab and tumor response was first seen
2 months thereafter, the time to response would be on
the far end of what has been reported for anti-PD-1
immunotherapy in various types of cancer, with most
clinical trials showing a median time to response of
around 2 months [20–29]. Notably, re-irradiation using
modern external beam radiation techniques to apply
high biological doses (with or without brachytherapy)
has been shown to achieve adequate local control rates in
various series of recurrent nasopharyngeal carcinoma, utiliz-
ing both standard fractionation as well as hypofractionated
regimens and sometimes chemotherapy as a radiosensitizer
[30–32]. It is therefore difficult to discriminate good local
control achieved by radiation from synergistic effects of
any bimodality treatment. However, given the extent
and duration of response to a very moderate dose of
45 Gy in fractions of 1.8 Gy, we considered attribution
of local control solely to radiotherapy as very unlikely,
particularly since parts of the target volume had previously
been re-irradiated using CyberKnife® without lasting effect.
Checkpoint inhibitor immunotherapy is associated with
a unique spectrum of immune-related adverse events,
reflecting its underlying mechanisms of action aiming at T
cell activation and enhanced antitumor immune response
[33, 34]. While dermatologic toxicity is the most common
(and often the earliest) inflammatory side effect, possible
immune-related adverse events include mucosal and
gastrointestinal toxicities, pneumonitis, hepatotoxicity,
endocrinopathies and (more rarely) neurologic, renal,
Fig. 6 T1-weighted MRI in December of 2016 showing signs of inflammation with marked swelling of salivary glands (sublingual, red arrow;
submandibular, blue arrows; parotids, orange arrows) as well as lacrimal glands (green arrows)
Fig. 7 T1-weighted MRI in May of 2017 demonstrating ongoing,
subtotal tumor response
Finazzi et al. BMC Cancer  (2018) 18:395 Page 5 of 7
pancreatic and ocular toxicities [35]. Although the clinical
signs seen in our patient (mucosal, including nasal and
ocular, irritation; swelling of lacrimal and salivary glands;
maculopapular rash) might well represent disorders of
infectious and allergic nature, we believe that the assump-
tion of immunostimulation as a common cause following
irradiation under anti-PD-1 immunotherapy is reasonable,
given the clinical course. Of note, dermatologic toxicities
and radiological signs of immune-related adverse events
have been associated with better outcome in patients
treated with checkpoint inhibitor immunotherapy,
although generalization of these observations is not
possible [36–39].
The concept of a synergistic effect of radiotherapy and
immune checkpoint inhibitors aiming at enhanced response
rates and potential long term tumor control is based on an
increasing amount of encouraging preclinical and clinical
evidence [17–19, 40–44]. Radiation hereby acts as an im-
mune stimulus, recruiting cytokines that enable anti-tumor
responses within and outside the radiation field [45]. While
the immunogenic properties of radiation (including obser-
vations of an abscopal effect following radiotherapy as an
otherwise rare clinical phenomenon) have long been dis-
cussed, the emergence of immunotherapy and the growing
amount of preclinical data have moved the rationale of
a combined treatment approach into the spotlight of
research, potentially indicating a paradigm shift in the
utilization of radiotherapy in these patients [45–47].
Understandably, these observations have also sparked a
particular interest in the management of heavily pretreated
patients with limited options for effective salvage treat-
ment, such as the case presented. However, with trials
combining radiotherapy and immune checkpoint inhibi-
tors currently ongoing [45], the remaining uncertainties
surrounding the role and clinical implication of these
approaches need to be emphasized.
In summary, we observed an excellent response to
combined immunotherapy and re-re-irradiation in a case
of recurrent nasopharyngeal carcinoma, and we are hopeful
to see future developments that improve outcomes for
these patients with otherwise limited treatment options.
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